ABSTRACT
Background: Sodium valproate [SV] has been approved for migraine prophylaxis and its intravenous form is used to treat acute migraine attacks. We compared the efficacy and safety of intravenous SV and subcutaneous Sumatriptan in managing acute migraine attacks
Methods: This double-blind randomized clinical trial divided 90 patients into two groups: one group received 400 mg of intravenous SV and the second group received 6 mg of subcutaneous Sumatriptan. Headache severity before treatment and half an hour, one hour, and two hours after treatment was measured based on the VNRS in the groups. Associated symptoms, i.e., photophobia, phonophobia, nausea, and vomiting, were assayed on admission and 2 hours after treatment. Side effects of the drugs were checked 2 hours after injection. Obtained data from the groups were compared
Results: In both groups, pain decrement at the mentioned time points was significant [P<0.001], but had no significant difference [P>0.05], indicating the similar effect of both drugs on pain improvement. In the SV group, photophobia, phonophobia, nausea, and vomiting were improved significantly, while in the Sumatriptan group, only photophobia and vomiting were decreased significantly, indicating the advantage of SV in improving the associated symptoms. Nausea, vomiting, facial paresthesia, and hypotension were more significantly frequent in the Sumatriptan group than in the SV group [P<0.05]
Conclusion: Intravenous SV [400 mg] was as effective as subcutaneous Sumatriptan in the treatment of acute migraine attacks, but with more improvement in associated symptoms and with fewer side effects
ABSTRACT
The aim of this study was to determine the prevalence and risk factors of the sensory neuropathy in type 2 diabetic patients referring to Yazd Diabetes Research Center. Neuropathy is one of the most common complications of both type 1 and type 2 diabetes mellitus. This is a cross-sectional study on 2350 diabetic patients [1071 male, 1279 female] referred to Yazd Diabetes Research Center [Iran] from June 2007 to February 2208. Data collection was carried out through a questionnaire including demographic subject, duration, body weight and length, lab test [HbA1c, 2hpp, FBS], Body Mass Index [BMI]. Blood Pressure was measured on the right arm after a five-min rest. Neuropathy was confirmed using a Semmes Weinstein 10g monofilament over 10 areas of the feet, ankle reflexes and vibration over the great toe and ankle. The prevalence of type 2 diabetes and diabetic sensory neuropathy in Yazd province in 14.5% and 51.7%, respectively. The prevalence of sensory neuropathy in male was 49.9% and 53.2% in female, that increased by age [P=0.001], duration of diabetes [P=0.001], HbA1c [P=0.001] and poor glycemic control [high FBS and 2hpp]. Age, duration of diabetes, HbA1c and poor glycemic control were considered to be the risk factors for sensory neuropathy